Literature DB >> 35224605

Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting.

Jonathan Yap1, Mun Yee Tham, Jalene Poh, Dorothy Toh, Cheng Leng Chan, Toon Wei Lim, Shir Lynn Lim, Yew Woon Chia, Yean Teng Lim, Jonathan Choo, Zee Pin Ding, Ling Li Foo, Simin Kuo, Yee How Lau, Annie Lee, Khung Keong Yeo.   

Abstract

INTRODUCTION: Despite reports suggesting an association between COVID-19 mRNA vaccination and pericarditis and myocarditis, detailed nationwide population-based data are sparsely available. We describe the incidence of pericarditis and myocarditis by age categories and sex after COVID-19 mRNA vaccination from a nationwide mass vaccination programme in Singapore.
METHODS: The incidence of adjudicated cases of pericarditis and myocarditis following COVID-19 mRNA vaccination that were reported to the vaccine safety committee between January to July 2021 was compared with the background incidence of myocarditis in Singapore.
RESULTS: As of end July 2021, a total of 34 cases were reported (9 pericarditis only, 14 myocarditis only, and 11 concomitant pericarditis and myocarditis) with 7,183,889 doses of COVID-19 mRNA vaccine administered. Of the 9 cases of pericarditis only, all were male except one. The highest incidence of pericarditis was in males aged 12-19 years with an incidence of 1.11 cases per 100,000 doses. Of the 25 cases of myocarditis, 80% (20 cases) were male and the median age was 23 years (range 12-55 years) with 16 cases after the second dose. A higher-than-expected number of cases were seen in males aged 12-19 and 20-29 years, with incidence rates of 3.72 and 0.98 case per 100,000 doses, respectively.
CONCLUSION: Data from the national registry in Singapore indicate an increased incidence of pericarditis and myocarditis in younger men after COVID-19 mRNA vaccination.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35224605

Source DB:  PubMed          Journal:  Ann Acad Med Singap        ISSN: 0304-4602            Impact factor:   2.473


  6 in total

Review 1.  Recurrent Pericarditis: a Stubborn Opponent Meets New Treatments in 2022.

Authors:  Tracy Hagerty; Matthew A Kluge; Martin M LeWinter
Journal:  Curr Cardiol Rep       Date:  2022-05-25       Impact factor: 3.955

2.  Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature.

Authors:  Samantha Lane; Alison Yeomans; Saad Shakir
Journal:  BMJ Open       Date:  2022-05-25       Impact factor: 3.006

3.  Correspondence on 'BNT162b2 vaccine-associated myo/pericarditis in adolescents'.

Authors:  Pathum Sookaromdee; Viroj Wiwanitkit
Journal:  Eur J Clin Invest       Date:  2022-04-02       Impact factor: 5.722

Review 4.  Myocarditis or Pericarditis Following the COVID-19 Vaccination in Adolescents: A Systematic Review.

Authors:  Minglong Li; Xingxing Wang; Junjie Feng; Ziqi Feng; Wenwen Li; Bailiu Ya
Journal:  Vaccines (Basel)       Date:  2022-08-15

5.  Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.

Authors:  Congqin Chen; Fang Fu; Lingqing Ding; Jie Fang; Jie Xiao
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

Review 6.  A Systematic Review and Meta-analysis of the Association Between SARS-CoV-2 Vaccination and Myocarditis or Pericarditis.

Authors:  Juan Gao; Linya Feng; Yaru Li; Scott Lowe; Zhichun Guo; Rachel Bentley; Chuman Xie; Birong Wu; Peng Xie; Weihang Xia; Shaodi Ma; Haixia Liu; Xianwei Guo; John Patrick N Uy; Qin Zhou; Hina Wazir; Chenyu Sun
Journal:  Am J Prev Med       Date:  2022-09-26       Impact factor: 6.604

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.